keyword
MENU ▼
Read by QxMD icon Read
search

Active surveillance prostate

keyword
https://www.readbyqxmd.com/read/28814450/in-localised-prostate-cancer-radical-prostatectomy-was-associated-with-more-sexual-dysfunction-and-urinary-incontinence-than-radiation-or-active-surveillance
#1
Zachary L Smith, Scott E Eggener
No abstract text is available yet for this article.
August 16, 2017: Evidence-based Medicine
https://www.readbyqxmd.com/read/28801885/active-surveillance-for-intermediate-risk-prostate-cancer
#2
REVIEW
Laurence Klotz
PURPOSE OF REVIEW: Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad consensus that men with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 disease, PSA >10, younger men and African-Americans are often excluded. RECENT FINDINGS: Outcome data for intermediate-risk patients managed by active surveillance demonstrate reasonable outcomes, but these men clearly are at higher risk for progression to metastatic disease...
August 11, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28801241/trends-in-radical-prostatectomy-risk-group-distribution-in-a-european-multicenter-analysis-of-28-572-patients-towards-tailored-treatment
#3
Roderick van den Bergh, Giorgio Gandaglia, Derya Tilki, Hendrik Borgmann, Piet Ost, Christian Surcel, Massimo Valerio, Prasanna Sooriakumaran, Alberto Briganti, Markus Graefen, Henk van der Poel, Alexandre de la Taille, Francesco Montorsi, Guillaume Ploussard
BACKGROUND: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. OBJECTIVE: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam)...
August 8, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28798822/an-assessment-of-prostate-cancer-research-international-active-surveillance-prias-criteria-for-active-surveillance-of-clinically-low-risk-prostate-cancer-patients
#4
Vitor da Silva, Ilias Cagiannos, Luke T Lavallée, Ranjeeta Mallick, Kelsey Witiuk, Sonya Cnossen, James A Eastham, Dean A Fergusson, Chris Morash, Rodney H Breau
INTRODUCTION: Active surveillance is a strategy to delay or prevent treatment of indolent prostate cancer. The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were developed to select patients for prostate cancer active surveillance. The objective of this study was to compare pathological findings from PRIAS-eligible and PRIAS-ineligible clinically low-risk prostate cancer patients. METHODS: A D'Amico low-risk cohort of 1512 radical prostatectomy patients treated at The Ottawa Hospital or Memorial Sloan Kettering Cancer Centre between January 1995 and December 2007 was reviewed...
August 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28789947/impact-of-5%C3%AE-reductase-inhibitors-on-disease-reclassification-among-men-on-active-surveillance-for-localized-prostate-cancer-with-favorable-features
#5
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Daniel J Greene, Daniel Hettel, Chad Reichard, Samuel C Haywood, Hans Arora, Anna Zampini, Alice Crane, Jianbo Li, Ahmed Elshafei, Cristina Magi-Galluzzi, Robert J Stein, Khaled Fareed, Michael Gong, J Stephen Jones, Eric A Klein, Andrew J Stephenson
PURPOSE: To determine the effect of 5α-reductase inhibitors (5-ARI) on disease reclassification in men with prostate cancer optimally selected for active surveillance (AS). MATERIALS AND METHODS: A retrospective review identified 635 patients on AS between 2002-2015. Patients with favorable cancer features on repeat biopsy, defined as absence of Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride/dutasteride within 1 year of diagnosis...
August 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28789928/engaging-patients-in-complex-clinical-decision-making-successes-pitfalls-and-future-directions
#6
REVIEW
Aaron A Laviana, Stephanie C Pannell, Kathy H Y Huen, Jonathan Bergman
BACKGROUND: By 2022, there will be 18 million predicted cancer survivors, which is an estimated 30% more than the number of survivors in 2012. In prostate cancer alone, the most common cancer in American men other than skin cancer, 1 in 7 men will be diagnosed during their lifetime. Nevertheless, only approximately 1 in 39 will actually die of the disease. Although life expectancy is often good, these men have multiple treatment management options to choose from, including active surveillance, surgery, or radiotherapy, each of which carries its own array of long-term adverse effects...
August 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28789835/utility-of-anterior-zone-biopsy-in-men-enrolled-in-active-surveillance-for-prostate-cancer
#7
Allison S Glass, Neil B Pugashetti, Marc A Dall'Era, Christopher P Evans, Stanley A Yap
BACKGROUND: Anterior zone (AZ) disease is present in one-fifth of men with newly diagnosed prostate cancer and has been associated with poor pathologic features. However, anterior targeted biopsies are not a routine part of active surveillance (AS) protocols. Our purpose is to assess the utility of AZ sampling for prostate biopsy in patients undergoing surveillance for low-risk prostate cancer. METHODS: A prospective data collection of men enrolled in AS between 2006 and 2014 was performed...
July 14, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28789623/the-cost-effectiveness-of-active-surveillance-compared-to-watchful-waiting-and-radical-prostatectomy-for-low-risk-localised-prostate-cancer
#8
Chunhuan Lao, Richard Edlin, Paul Rouse, Charis Brown, Michael Holmes, Peter Gilling, Ross Lawrenson
BACKGROUND: Radical prostatectomy is the most common treatment for localised prostate cancer in New Zealand. Active surveillance was introduced to prevent overtreatment and reduce costs while preserving the option of radical prostatectomy. This study aims to evaluate the cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy. METHODS: Markov models were constructed to estimate the life-time cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer patients aged 45-70 years, using national datasets in New Zealand and published studies including the SPCG-4 study...
August 8, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28777452/active-surveillance-helps-prostate-cancer-patients-keep-quality-of-life-findings-show
#9
Carrie Printz
No abstract text is available yet for this article.
August 15, 2017: Cancer
https://www.readbyqxmd.com/read/28762545/epigenetic-risk-score-improves-prostate-cancer-risk-assessment
#10
Leander Van Neste, Jack Groskopf, William E Grizzle, George W Adams, Mark S DeGuenther, Peter N Kolettis, James E Bryant, Gary P Kearney, Michael C Kearney, Wim Van Criekinge, Sandra M Gaston
BACKGROUND: Early detection of aggressive prostate cancer (PCa) remains crucial for effective treatment of patients. However, PCa screening remains controversial due to a high rate of overdiagnosis and overtreatment. To better reconcile both objectives, more effective methods for assessing disease severity at the time of diagnosis are needed. METHODS: The relationship between DNA-methylation and high-grade PCa was examined in a cohort of 102 prospectively enrolled men who received standard 12-core prostate biopsies...
August 1, 2017: Prostate
https://www.readbyqxmd.com/read/28757301/quality-of-life-outcomes-after-primary-treatment-for-clinically-localised-prostate-cancer-a-systematic-review
#11
REVIEW
Michael Lardas, Matthew Liew, Roderick C van den Bergh, Maria De Santis, Joaquim Bellmunt, Thomas Van den Broeck, Philip Cornford, Marcus G Cumberbatch, Nicola Fossati, Tobias Gross, Ann M Henry, Michel Bolla, Erik Briers, Steven Joniau, Thomas B Lam, Malcolm D Mason, Nicolas Mottet, Henk G van der Poel, Olivier Rouvière, Ivo G Schoots, Thomas Wiegel, Peter-Paul M Willemse, Cathy Yuhong Yuan, Liam Bourke
CONTEXT: Current evidence-based management for clinically localised prostate cancer includes active surveillance, surgery, external beam radiotherapy (EBRT) and brachytherapy. The impact of these treatment modalities on quality of life (QoL) is uncertain. OBJECTIVE: To systematically review comparative studies investigating disease-specific QoL outcomes as assessed by validated cancer-specific patient-reported outcome measures with at least 1 yr of follow-up after primary treatment for clinically localised prostate cancer...
July 27, 2017: European Urology
https://www.readbyqxmd.com/read/28753869/pten-loss-but-not-erg-expression-in-diagnostic-biopsies-is-associated-with-increased-risk-of-progression-and-adverse-surgical-findings-in-men-with-prostate-cancer-on-active-surveillance
#12
Utku Lokman, Andrew M Erickson, Hanna Vasarainen, Antti S Rannikko, Tuomas Mirtti
BACKGROUND: Active surveillance (AS) is an option for men with low-risk prostate cancer (PCa). PTEN and ERG have been considered as potential biomarkers of PCa progression and survival. OBJECTIVE: To study the role of ERG and PTEN status in the Prostate Cancer Research International: Active Surveillance (PRIAS) trial diagnostic biopsies (DBxs) in predicting surveillance discontinuation and adverse surgical findings in subsequent radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: A total of 231 patients were recruited to the PRIAS between 2007 and 2013 in Helsinki...
March 22, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753865/prognostic-biomarkers-used-for-localised-prostate-cancer-management-a-systematic-review
#13
REVIEW
Pierre-Jean Lamy, Yves Allory, Anne-Sophie Gauchez, Bernard Asselain, Philippe Beuzeboc, Patricia de Cremoux, Jacqueline Fontugne, Agnès Georges, Christophe Hennequin, Jacqueline Lehmann-Che, Christophe Massard, Ingrid Millet, Thibaut Murez, Marie-Hélène Schlageter, Olivier Rouvière, Diana Kassab-Chahmi, François Rozet, Jean-Luc Descotes, Xavier Rébillard
CONTEXT: Prostate cancer stratification is based on tumour size, pretreatment PSA level, and Gleason score, but it remains imperfect. Current research focuses on the discovery and validation of novel prognostic biomarkers to improve the identification of patients at risk of aggressive cancer or of tumour relapse. OBJECTIVE: This systematic review by the Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) analysed new evidence on the analytical validity and clinical validity and utility of six prognostic biomarkers (PHI, 4Kscore, MiPS, GPS, Prolaris, Decipher)...
March 7, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753811/risk-of-upgrading-and-upstaging-among-10-000-patients-with-gleason-3-4-favorable-intermediate-risk-prostate-cancer
#14
David D Yang, Brandon A Mahal, Vinayak Muralidhar, Michelle D Nezolosky, Marie E Vastola, Shelby A Labe, Ninjin Boldbaatar, Martin T King, Neil E Martin, Peter F Orio, Clair J Beard, Karen E Hoffman, Quoc-Dien Trinh, Daniel E Spratt, Felix Y Feng, Paul L Nguyen
BACKGROUND: It is unknown whether active surveillance can be safely offered to patients with Gleason 3+4 favorable intermediate-risk (FIR) prostate cancer. OBJECTIVE: To examine the incidence and predictors of upgrading and upstaging among patients with Gleason 3+4 FIR disease. DESIGN, SETTING, AND PARTICIPANTS: The study involved 10 089 patients in the National Cancer Database diagnosed from 2010 to 2012 with Gleason 3+4 disease, prostate-specific antigen (PSA) <10ng/ml, and cT1c-2a prostate cancer with <50% positive biopsy cores (PBCs) who underwent radical prostatectomy...
June 17, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753804/variability-in-outcomes-for-patients-with-intermediate-risk-prostate-cancer-gleason-score-7-international-society-of-urological-pathology-gleason-group-2-3-and-implications-for-risk-stratification-a-systematic-review
#15
REVIEW
Christopher J Kane, Scott E Eggener, Alan W Shindel, Gerald L Andriole
CONTEXT: Optimal management for patients with intermediate-risk (IR) prostate cancer (PCa) remains controversial. Clinical metrics provide guidance on appropriate management options. OBJECTIVE: To report estimates for clinically relevant outcomes in men with IR PCa based on clinical and pathological features. EVIDENCE ACQUISITION: PubMed and programs from key 2015 uro-oncology congresses were searched using the terms "intermediate", "Gleason 3 + 4", "Gleason 4 + 3", "active surveillance", "treatment", "adverse pathology", AND "prostate cancer...
March 11, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28747132/prostate-cancer-in-bore-magnetic-resonance-guided-biopsies-at-active-surveillance-inclusion-improve-selection-of-patients-for-active-treatment
#16
Maria Carlsen Elkjær, Morten Heebøll Andersen, Søren Høyer, Bodil Ginnerup Pedersen, Michael Borre
Background Active surveillance (AS) of low-risk prostate cancer (PCa) is an accepted alternative to active treatment. However, the conventional diagnostic trans-rectal ultrasound guided biopsies (TRUS-bx) underestimate PCa aggressiveness in almost half of the cases, when compared with the surgical specimen. Purpose To investigate if additional multi-parametric magnetic resonance imaging (mpMRI) of the prostate and MRI-guided in-bore biopsies (MRGB) at AS inclusion would improve selection of patients for active treatment...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28740904/disparities-in-staging-prostate-magnetic-resonance-imaging-utilization-for-nonmetastatic-prostate-cancer-patients-undergoing-definitive-radiation-therapy
#17
Ayobami Ajayi, Wei-Ting Hwang, Neha Vapiwala, Mark Rosen, Christina H Chapman, Stefan Both, Meera Shah, Xingmei Wang, Atu Agawu, Peter Gabriel, John Christodouleas, Zelig Tochner, Curtiland Deville
PURPOSE: There is growing evidence supporting incorporating multiparametric (mp) magnetic resonance imaging (MRI) scans into risk stratification, active surveillance, and treatment paradigms for prostate cancer. The purpose of our study was to determine whether demographic disparities exist in staging MRI utilization for prostate cancer patients. METHODS AND MATERIALS: An institutional database of 705 nonmetastatic prostate cancer patients treated with radiation therapy from 2005 through 2013 was used to identify patients undergoing versus not undergoing pretreatment diagnostic prostate mpMRI...
October 2016: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/28736249/identifying-intermediate-risk-candidates-for-active-surveillance-of-prostate-cancer
#18
Richard Savdie, Jonathan Aning, Alan I So, Peter C Black, Martin E Gleave, S Larry Goldenberg
PURPOSE: Although already established for very-low and low-risk (LR) prostate cancer (PCa), controversy remains around offering active surveillance (AS) to men with intermediate-risk (IR) PCa. As IR represents a broad spectrum of disease biology, there is a critical need to define eligibility criteria that will enable both patient and physician to accept AS as the best balance of competing risks. In this study, we aimed to identify predictors of progression to enable optimal patient selection...
July 20, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28728993/value-of-tracking-biopsy-in-men-undergoing-active-surveillance-of-prostate-cancer
#19
Edward Chang, Tonye A Jones, Shyam Natarajan, Devi Sharma, Demetrios Simopoulos, Daniel J Margolis, Jiaoti Huang, Frederick J Dorey, Leonard S Marks
PURPOSE: To compare the upgrading rate obtained by re-sampling precise spots of prostate cancer (tracking biopsy) vs conventional systematic re-sampling, during follow-up of; men in active surveillance. MATERIALS AND METHODS: Subjects were all 352 men, from 2009 to 2017, with Gleason 3+3 (n=268) or Gleason 3+4 (n=84) prostate cancer at initial MRI/ultrasound fusion biopsy and who subsequently had a second fusion biopsy. At first biopsy session, all men underwent 12-core systematic biopsies and, when MRI-visible lesions were present, targeted biopsies...
July 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28725591/diffusion-weighted-imaging-of-the-prostate-principles-application-and-advances
#20
REVIEW
Martin H Maurer, Johannes T Heverhagen
This review article aims to provide an overview on the principles of diffusion-weighted magnetic resonance imaging (DW-MRI) and its applications in the imaging of the prostate. DW-MRI with regards to different applications for prostate cancer (PCa) detection and characterization, local staging as well as for active surveillance (AS) and tumor recurrence after radical prostatectomy (RP) will be discussed. Furthermore, advances in DW-MRI techniques like diffusion kurtosis imaging (DKI) will be presented.
June 2017: Translational Andrology and Urology
keyword
keyword
109735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"